恒瑞医药(01276)：HRS-2162注射液获药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-2162 injection, a new generation muscle relaxant antagonist [1] Group 1 - HRS-2162 injection is designed to counteract the pharmacological effects of muscle relaxants and rapidly restore muscle tone [1] - Currently, there are no similar products approved for marketing in both domestic and international markets [1] - The total research and development investment for the HRS-2162 injection project has reached approximately 28.25 million yuan [1]